A review on interplay between obesity, lipoprotein profile and nutrigenetics with selected candidate marker genes of type 2 diabetes mellitus

Bhori, Mustansir; Rastogi, Varuni; Tungare, Kanchanlata; Marar, Thankamani

doi:10.1007/s11033-021-06837-5

Cited by 6 publications

(3 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genetics plays a significant role in T2DM development [ 19 ], with body weight, height, and abdominal fat as known risk factors [ 20 ]. However, environmental factors such as diet also play a major role in the development and reversal of T2DM markers [ 21 , 22 ].…”

Section: Introductionmentioning

confidence: 99%

The Geroprotective Drug Candidate CMS121 Alleviates Diabetes, Liver Inflammation, and Renal Damage in db/db Leptin Receptor Deficient Mice

Zahid

Dafre

Currais

et al. 2023

IJMS

View full text Add to dashboard Cite

db/db mice, which lack leptin receptors and exhibit hyperphagia, show disturbances in energy metabolism and are a model of obesity and type 2 diabetes. The geroneuroprotector drug candidate CMS121 has been shown to be effective in animal models of Alzheimer’s disease and aging through the modulation of metabolism. Thus, the hypothesis was that CMS121 could protect db/db mice from metabolic defects and thereby reduce liver inflammation and kidney damage. The mice were treated with CMS121 in their diet for 6 months. No changes were observed in food and oxygen consumption, body mass, or locomotor activity compared to control db/db mice, but a 5% reduction in body weight was noted. Improved glucose tolerance and reduced HbA1c and insulin levels were also seen. Blood and liver triglycerides and free fatty acids decreased. Improved metabolism was supported by lower levels of fatty acid metabolites in the urine. Markers of liver inflammation, including NF-κB, IL-18, caspase 3, and C reactive protein, were lowered by the CMS121 treatment. Urine markers of kidney damage were improved, as evidenced by lower urinary levels of NGAL, clusterin, and albumin. Urine metabolomics studies provided further evidence for kidney protection. Mitochondrial protein markers were elevated in db/db mice, but CMS121 restored the renal levels of NDUFB8, UQCRC2, and VDAC. Overall, long-term CMS121 treatment alleviated metabolic imbalances, liver inflammation, and reduced markers of kidney damage. Thus, this study provides promising evidence for the potential therapeutic use of CMS121 in treating metabolic disorders.

show abstract

Section: Introductionmentioning

confidence: 99%

The Geroprotective Drug Candidate CMS121 Alleviates Diabetes, Liver Inflammation, and Renal Damage in db/db Leptin Receptor Deficient Mice

Zahid

Dafre

Currais

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Group 3 and group 4 also showed higher percentage of males with CAD in presences and absence of co-morbidities. From worldwide prospective epidemiological research, the development of risk variables and their correlation with the manifestation of various disease have been determined (Bhori, Rastogi, Tungare, & Marar, 2022). Such studies have demonstrated a consistent link between attributes studied in healthy individuals and the prevalence of CAD.…”

Section: Resultsmentioning

confidence: 99%

Evaluation of the circulatory levels of resistin in coronary artery disease with associated co-morbidities

Kamble

Pandhare

Vidhate

et al. 2022

ijhs

View full text Add to dashboard Cite

Inflammation is known to be the root cause of the development of coronary artery disease (CAD). Subclinical inflammation is one of the key players in pathophysiology of CAD. An inflammatory response leads to the secretion of various adipokines and cytokines. There are various pro-inflammatory markers which could be used to determine the onset of disease, and one such marker is resistin adipokine. The present study evaluates and compares the circulatory concentration of resistin in CAD patients and controls for the determination of its association with CAD. In this study, 58 CAD patients were enrolled and were further subdivided into four groups as per the associated co-morbidities. Various anthropometric and biochemical parameters were assessed. The circulatory levels of resistin were found to be significantly elevated in CAD patients and their subgroups as compared to controls. We conclude that elevated resistin levels in CAD patients suggest a key role of resistin in the development of CAD. The present study also observed that co-morbidities like type 2 diabetes can act as one of the major factors for the elevated concentration of resistin in the circulation of CAD patients with diabetes.

show abstract

“…IR is defined as the inability of insulin to regulate glucose homeostasis of target tissues, which is a systemic condition and asymptomatic resulting in extreme difficulties for prevention and treatment (4,5). For the last few decades, only a few advanced developments have been made for the treatment of IR and it's therefore necessary to find more effective therapeutic strategies for T2D patients (6)(7)(8).…”

Section: Introductionmentioning

confidence: 99%

Faecalibacterium prausnitzii Improves Lipid Metabolism Disorder and Insulin Resistance in Type 2 Diabetic Mice

Xuan¹,

Chen

et al. 2023

Br J Biomed Sci

View full text Add to dashboard Cite

Purpose: Additional effective therapeutic strategies for Type 2 diabetes (T2D) patients are urgently needed. Gut microbiota plays an important role in T2D development and is a promising treatment strategy for T2D patients. Faecalibacterium prausnitzii (F. prausnitzii) is regarded as one of the most important bacterial indicators for a healthy gut, but the mechanisms of its anti-diabetic properties are still unclear.Methods and Results: The abundance of F. prausnitzii in feces of patients with T2D was detected by using qPCR. The effects of F. prausnitzii on glucose homeostasis, insulin resistance (IR), dyslipidemia, hepatic steatosis and inflammation were investigated in type 2 diabetic (T2D) db/db mice. We also investigated F. prausnitzii in people. Our results showed that the abundance of F. prausnitzii was significantly lower in T2D patients compared to healthy subjects. In T2D mice, we found that F. prausnitzii treatment significantly decreased fasting blood glucose and IR index, indicating improved glucose intolerance as well as IR. Furthermore, based on evaluation of lipid-regulating enzyme activities and proinflammatory cytokine levels, F. prausnitzii was not only able to improve inflammation in both adipose tissue and liver, but also ameliorate hepatic steatosis through inhibiting the activity of hepatic lipogenic enzymes.Conclusion: These results suggested that F. prausnitzii might serve as a therapeutic option for T2D by improved IR, lipid metabolism and inflammation.

show abstract

A review on interplay between obesity, lipoprotein profile and nutrigenetics with selected candidate marker genes of type 2 diabetes mellitus

Cited by 6 publications

References 149 publications

The Geroprotective Drug Candidate CMS121 Alleviates Diabetes, Liver Inflammation, and Renal Damage in db/db Leptin Receptor Deficient Mice

The Geroprotective Drug Candidate CMS121 Alleviates Diabetes, Liver Inflammation, and Renal Damage in db/db Leptin Receptor Deficient Mice

Evaluation of the circulatory levels of resistin in coronary artery disease with associated co-morbidities

Faecalibacterium prausnitzii Improves Lipid Metabolism Disorder and Insulin Resistance in Type 2 Diabetic Mice

Contact Info

Product

Resources

About